vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and RISKIFIED LTD. (RSKD). Click either name above to swap in a different company.
RISKIFIED LTD. is the larger business by last-quarter revenue ($234.0M vs $207.8M, roughly 1.1× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs -13.2%, a 70.6% gap on every dollar of revenue.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
Riskified is a publicly traded software company headquartered in Tel Aviv, Israel, with additional offices in New York City. The company provides software-as-a-service (SaaS) solutions focused on fraud prevention, chargeback management, and risk intelligence for e-commerce merchants.
IDYA vs RSKD — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $234.0M |
| Net Profit | $119.2M | $-30.8M |
| Gross Margin | — | 52.2% |
| Operating Margin | 52.2% | -19.0% |
| Net Margin | 57.4% | -13.2% |
| Revenue YoY | — | — |
| Net Profit YoY | 330.1% | — |
| EPS (diluted) | $1.33 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $207.8M | $234.0M | ||
| Q2 25 | — | $155.1M | ||
| Q1 25 | — | $76.4M | ||
| Q3 24 | $0 | $213.5M | ||
| Q2 24 | $0 | $141.7M | ||
| Q1 24 | $0 | $68.9M | ||
| Q3 22 | $29.7M | — |
| Q3 25 | $119.2M | $-30.8M | ||
| Q2 25 | — | $-21.1M | ||
| Q1 25 | — | $-11.6M | ||
| Q3 24 | $-51.8M | $-55.8M | ||
| Q2 24 | $-52.8M | $-34.8M | ||
| Q1 24 | $-39.6M | $-18.0M | ||
| Q3 22 | $1.6M | — |
| Q3 25 | — | 52.2% | ||
| Q2 25 | — | 53.6% | ||
| Q1 25 | — | 55.1% | ||
| Q3 24 | — | 48.7% | ||
| Q2 24 | — | 51.4% | ||
| Q1 24 | — | 52.0% | ||
| Q3 22 | — | — |
| Q3 25 | 52.2% | -19.0% | ||
| Q2 25 | — | -19.4% | ||
| Q1 25 | — | -20.8% | ||
| Q3 24 | — | -32.9% | ||
| Q2 24 | — | -31.8% | ||
| Q1 24 | — | -33.4% | ||
| Q3 22 | 2.2% | — |
| Q3 25 | 57.4% | -13.2% | ||
| Q2 25 | — | -13.6% | ||
| Q1 25 | — | -15.2% | ||
| Q3 24 | — | -26.1% | ||
| Q2 24 | — | -24.6% | ||
| Q1 24 | — | -26.1% | ||
| Q3 22 | 5.4% | — |
| Q3 25 | $1.33 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $-0.60 | — | ||
| Q2 24 | $-0.68 | — | ||
| Q1 24 | $-0.53 | — | ||
| Q3 22 | $0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $371.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $382.3M |
| Total Assets | $1.2B | $495.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $786.9M | $371.1M | ||
| Q2 25 | — | $371.1M | ||
| Q1 25 | — | $371.1M | ||
| Q3 24 | $920.0M | $440.8M | ||
| Q2 24 | $701.7M | $440.8M | ||
| Q1 24 | $698.8M | $440.8M | ||
| Q3 22 | $386.2M | — |
| Q3 25 | $1.1B | $382.3M | ||
| Q2 25 | — | $382.3M | ||
| Q1 25 | — | $382.3M | ||
| Q3 24 | $1.2B | $491.7M | ||
| Q2 24 | $931.7M | $491.7M | ||
| Q1 24 | $935.3M | $491.7M | ||
| Q3 22 | $368.8M | — |
| Q3 25 | $1.2B | $495.9M | ||
| Q2 25 | — | $495.9M | ||
| Q1 25 | — | $495.9M | ||
| Q3 24 | $1.2B | $601.9M | ||
| Q2 24 | $973.7M | $601.9M | ||
| Q1 24 | $961.5M | $601.9M | ||
| Q3 22 | $410.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | — |
| Free Cash FlowOCF − Capex | $142.2M | — |
| FCF MarginFCF / Revenue | 68.4% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 1.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $142.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $-49.2M | — | ||
| Q2 24 | $-32.9M | — | ||
| Q1 24 | $-43.8M | — | ||
| Q3 22 | $-24.2M | — |
| Q3 25 | $142.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $-49.7M | — | ||
| Q2 24 | $-33.9M | — | ||
| Q1 24 | $-45.1M | — | ||
| Q3 22 | $-25.3M | — |
| Q3 25 | 68.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | -85.1% | — |
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | 3.7% | — |
| Q3 25 | 1.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | -14.96× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
